Inventors:
Brian Dieckgraefe - Chesterfield MO, US
Joshua Korzenik - Boston MA, US
Assignee:
Washington University - St. Louis MO
International Classification:
A61K048/00, A61K031/415, A61K031/365
US Classification:
514/044000, 514/406000, 514/471000
Abstract:
Disruption of the Reg signalling pathway permits spontaneous and therapeutic induction of pro-apoptotic signals to be more effective. Disruption can be accomplished by means of antibodies, antisense, RNA interference, small molecule inhibitors, etc. These can be used in conjunction with conventional anti-neoplastic therapies. Inhibitors can be identified by assays that monitor the disruption of the binding of Reg ligands and the Reg ligand receptor.